The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2015 | Phase II trial: ATIR for ALL following haploidentical hematopoietic cell transplant
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Roy Denis-Claude, MD, from Maisonneuve-Rosemont Hospital and Montreal University, Montreal, QC, Canada, discusses the results of an open-label, multi-center phase 2 clinical trial, which showed donor lymphocytes depleted of alloreactive T cells (ATIR101) reduced transplant-related mortality and improved overall survival in haploidentical hematopoietic stem cell transplantation (HSCT) for patients with high-risk acute myeloid leukemia (AML) or acute lymphocytic leukemia (ALL), using an immunosuppressant-free transplant regimen.
